



ANRS RHIVIERA WORKSHOP, 2 avril 2021

10h: Welcome and introduction: ANRS RHIVIERA towards HIV remission Asier Sáez-Ciri3n & Christine Rouzioux

Session 1. Understanding HIV-1 control or rebound after treatment interruption. ANRS VISCONTI (NIH)

10h15- A clinical update on the post-treatment controllers in the VISCONTI study Laurent Hocqueloux (CH Orl3ans)

10h30- A genetic fingerprint associated with durable HIV remission after interruption of early ART Asier Sáez-Ciri3n (Institut Pasteur)

10h45- In-depth characterization of full-length archived HIV genomes in long-term post-treatment and natural HIV controller V3ronique Avettand-Fenoel (Institut Cochin)

11h00- Humoral Immunity in Post-treatment controllers Hugo Mouquet (Institut Pasteur)

Session 2. Targeting viral reservoirs (Partnership with ViiV Healthcare)

11h15- WP2, Imaging drug diffusion and viral reservoirs Roger Le Grand (IDMIT)

11h30- PET-CT Imaging of SIV Replication in NHP Catherine Chapon (IDMIT)

11h45- Characterization of ARV Distribution in tissues Thibaut Gel3 (IDMIT)

12h00- Yazdan Yazdanpanah, (ANRS director) RHIVIERA and remission studies in the ANRS-MIE

12h15- WP1, Heterogeneity of mechanisms responsible for HIV-1 gene silencing Carine Van Lint (Universit3 Libre de Bruxelles)

12h30- CTIP2 partners as molecular targets to shock HIV in myeloid lineage Olivier Rohr (IPPTS)

12h45- Modulation of the immune responses with remission perspectives Olivier Lambotte (CHU Bic3tre)

13h00-14h00 PAUSE



Session 3. A non-human primate model for HIV remission (partnership with MSDAVENIR)

14h00- p(ri)mate)VISCONTI study design and objectives Delphine Desjardin (IDMIT)

14h15- Impact of early ART on immune responses and post-treatment SIV control Caroline Passaes (Institut Pasteur)

14h30- Characterization of SIV dynamics in a NHP model of SIVmac251 infection Véronique Avettand-Fenoel (Institut Cochin)

14h45- Neutrophil diversity and immunomodulatory function during SIV infection and antiretroviral treatment Julien Lemaitre (IDMIT)

15h00- Features of tissue adaptive NK cells during SIV infection: lessons from a natural host Nicolas Huot (Institut Pasteur)

Session 4. Clinical trials aiming HIV-1 remission (ANRS)

15h15- RHIVIERA 01: Assessment of HIV remission upon cART interruption in early treated individuals from ANRS CO6 PRIMO cohort carrying the MHC genotype B35(53)Bw4TTC2 Laurence Meyer (INSERM)

15h30- Invited speaker: Broadly Neutralizing Antibodies for HIV Prevention, Therapy and Cure Marina Caskey (Rockefeller University)

16h00- RHIVIERA 02: a randomized multicentric control trial testing the impact on post-treatment HIV control of dual long-acting HIV-specific bNAbs in combination with ART in HIV infected individuals undergoing primary HIV-1 infection. Cecile Goujard (CHU Bicêtre)

16h15- Experience, motivation and reluctance to participate in clinical trials with ATI aiming HIV cure/remission Christel Protiere (Sesstim)

- Involvement and expectations of PWH in HIV remission studies: Hugues Fsher (trt5)/ Alain Volny- Anne (TBC)(Aidsmap)

17h00- Conclusion Asier Sáez-Ciri3n